Update: COPD medicines under review

Thursday, 5 Nov 2015

The deadline for submissions to the post-market review of COPD medicines has been extended.

The review was given the green light by the PBAc in August following concerns about the multiple use of a number of new combinations available on the PBS, including long-acting muscarinic antagonist (LAMA)/LABA and LABA/inhaled corticosteroid (ICS) combinations.

You now have until the 13th November. Click here for more information.

Already a member?

Login to keep reading.

Email me a login link

© 2022 the limbic